Is tirzepatide better than semaglutide for weight loss?

In the published head-to-head data (SURPASS-2, NEJM 2021), tirzepatide outperformed semaglutide 1mg on both HbA1c reduction and weight loss in adults with type 2 diabetes. Cross-trial comparison of obesity endpoints (SURMOUNT-1 vs STEP-1) gives tirzepatide a larger reported mean weight loss percentage at top dose (~22.5% vs ~14.9%) but those are separate trials, different populations, and different durations - so it's a strong signal, not a definitive randomised comparison.

What is the mechanistic difference between them?

Semaglutide is a single-receptor agonist - it only activates the GLP-1 receptor. Tirzepatide is a dual agonist - it activates both GLP-1 AND the GIP receptor in a single molecule. The added GIP activation supports insulin secretion and adipose-tissue lipid handling, and the empirical effect in trials has been additional weight loss and HbA1c reduction on top of what GLP-1 alone produces.

Why does tirzepatide cost more than semaglutide?

Tirzepatide is newer to market (FDA 2022 vs semaglutide's 2017) and currently has less competition. Mounjaro/Zepbound list prices in the US run $1,000-1,300 per month vs ~$900-1,300 for Ozempic/Wegovy. Insurance coverage is uneven for both. Research-grade material on the lab-reagent market - Tirzepatide and Semaglutide - tracks closer to raw-material economics and is therefore a much smaller fraction of the licensed-drug list price.

Should I take tirzepatide or semaglutide?

That is a treatment-selection decision a licensed prescriber must make, not a research-blog question. Mounjaro / Zepbound / Ozempic / Wegovy are prescription-only medicines and the decision turns on indication (T2D vs obesity), insurance coverage, side-effect tolerance, and comorbidities. New-U does not give treatment advice - we supply research-grade compounds as laboratory reagents only, not as substitutes for licensed prescriptions.

Shop by goal

Popular compounds

Research resources

Certificates of Analysis

Tirzepatide vs Semaglutide: The 2026 Research Comparison

This is the highest-volume comparison query in the metabolic peptide space - thousands of monthly US searches asking which molecule does what, which is "better", and how the two stack up on cost. It also happens to be the comparison most often answered with marketing fluff rather than data. This piece walks through what the actual published trials say.

RUO framing throughout. Mounjaro / Zepbound (tirzepatide) and Ozempic / Wegovy (semaglutide) are FDA-approved prescription medicines. New-U supplies research-grade equivalents - Tirzepatide (tirzepatide) and Semaglutide (semaglutide) - strictly as laboratory reagents, not as substitutes for the licensed products.

The Three-Sentence Summary

Semaglutide is a single-receptor GLP-1 agonist . Tirzepatide is a dual GLP-1 + GIP agonist . In the only published head-to-head trial (SURPASS-2), tirzepatide outperformed semaglutide on both HbA1c reduction and weight loss in T2D patients - and cross-trial comparison of obesity endpoints points the same direction at population level.

The Side-by-Side Comparison

Attribute Semaglutide Tirzepatide Development code NN9535 LY3298176 Manufacturer Novo Nordisk Eli Lilly Brand names Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D) Mounjaro (T2D), Zepbound (obesity, OSA-with-obesity) Receptor targets GLP-1 only GLP-1 + GIP (dual) FDA approval (T2D) 2017 May 2022 FDA approval (obesity) June 2021 November 2023 Top weekly dose 2.4mg (Wegovy) 15mg (Zepbound) Pivotal obesity trial STEP-1 (NEJM 2021) SURMOUNT-1 (NEJM 2022) Trial weight loss (top dose) ~14.9% at 68 weeks ~22.5% at 72 weeks Head-to-head T2D outcome SURPASS-2: HbA1c -1.86% at 1mg SURPASS-2: HbA1c -2.30% at 15mg (superior) CV outcomes evidence SELECT (positive, 2023) SURPASS-CVOT, SUMMIT (pending / partial) US list price (monthly) ~$900-1,300 ~$1,000-1,300 Research-grade equivalent Semaglutide Tirzepatide

The Mechanism Difference, Plain

Both peptides hit the GLP-1 receptor - which is what produces the appetite-suppression, slowed-gastric-emptying, glucose-dependent insulin-secretion effect that's been driving the entire weight-loss conversation since semaglutide launched.

Tirzepatide adds a second receptor target : GIP (glucose-dependent insulinotropic polypeptide). The biology was historically counter-intuitive - GIP receptor activation alone was associated with weight gain in earlier research. But when combined with GLP-1 activation, GIP appears to produce additional metabolic benefit: enhanced insulin secretion, improved adipose lipid handling, and additional weight loss on top of what GLP-1 alone delivers.

The mechanistic punchline: tirzepatide gives you GLP-1's appetite-and-glucose effects plus a second metabolic lever that semaglutide can't pull. For the longer mechanistic discussion, see our tirzepatide research guide.

The Head-to-Head Evidence: SURPASS-2

SURPASS-2 (Frias JP et al., NEJM, 2021) was the only large randomised head-to-head trial between tirzepatide and semaglutide. The setup:

Population : 1,879 adults with type 2 diabetes inadequately controlled on metformin

Duration : 40 weeks

Arms : Tirzepatide 5mg, 10mg, 15mg vs semaglutide 1mg

Primary endpoint : HbA1c change from baseline

Arm HbA1c change Mean weight loss Semaglutide 1mg -1.86% ~5.7 kg Tirzepatide 5mg -2.01% ~7.6 kg Tirzepatide 10mg -2.24% ~9.3 kg Tirzepatide 15mg -2.30% ~11.2 kg

All three tirzepatide doses beat semaglutide 1mg on both endpoints. The 15mg arm produced roughly double the weight loss of the semaglutide arm and a ~0.44% larger HbA1c reduction.

Important caveat. SURPASS-2 used semaglutide at 1mg - the T2D dose. The obesity dose of semaglutide is 2.4mg (Wegovy). There has not yet been a head-to-head trial of tirzepatide 15mg vs semaglutide 2.4mg in an obesity population. The cross-trial comparison (SURMOUNT-1 ~22.5% vs STEP-1 ~14.9%) is suggestive but is not a randomised head-to-head endpoint.

The Obesity Cross-Trial Comparison

Trial Drug Top dose Duration Mean weight loss Achieving ≥20% STEP-1 (2021) Semaglutide 2.4mg weekly 68 weeks ~14.9% ~32% SURMOUNT-1 (2022) Tirzepatide 15mg weekly 72 weeks ~22.5% ~57%

Different populations, different durations, different sponsors, different sites. The numbers are real but the comparison is approximate. A head-to-head SURMOUNT-vs-STEP-style trial in an obesity population has not yet been published - which is one reason the comparison-intent search query stays so high.

Side-Effect Profile: Roughly Similar

Both classes share the GLP-1 family GI signature: nausea, diarrhoea, constipation, vomiting , dose-dependent and worst during titration.

Discontinuation rates in SURPASS-2 were comparable between the semaglutide 1mg arm and the tirzepatide arms.

Both carry the GLP-1 class-wide rodent thyroid C-cell tumour box warning (no confirmed human signal at population level).

Pancreatitis risk and gallbladder disease are class-wide concerns.

Hair loss (telogen effluvium) reports are similar magnitude in both - covered in our companion piece on tirzepatide side effects research.

The Cost & Access Reality

Channel Semaglutide Tirzepatide US prescription list price ~$900-1,300/mo ~$1,000-1,300/mo Insurance coverage Patchy for obesity; better for T2D Patchy for obesity; OSA-with-obesity coverage expanding Compounded versions Off-shortage; 503A pathway closed Off-shortage; 503A pathway closed Research-grade reagent Semaglutide Tirzepatide EU / UK availability Wegovy widely available; NHS specialist-only Mounjaro / Zepbound widely available; NHS access limited

Both have come off the FDA shortage list, which means US compounding pharmacies operating under 503A and 503B can no longer compound them as a routine workaround. Patients without insurance coverage of the licensed brands face the full list price - which is the structural reason the research-grade reagent market has scaled in this space.

What This Means for Comparison Research

The head-to-head evidence (SURPASS-2) favours tirzepatide on both glucose and weight endpoints, but only at a single semaglutide dose (1mg) in a T2D population.

The cross-trial obesity comparison (SURMOUNT-1 vs STEP-1) also favours tirzepatide, but is approximate, not statistically equivalent.

The mechanistic case for the dual-receptor approach is consistent with the trial signal.

The cost is comparable at US list; insurance coverage drives the practical difference.

The verification step matters equally for both as research compounds - Janoshik / Freedom Diagnostics COAs are the only signal that separates a defensible vial from a counterfeit one. How to read a COA.

Status check. Mounjaro, Zepbound, Ozempic and Wegovy are FDA-approved prescription medicines and the decision between them is a licensed-prescriber decision, not research-blog content. New-U supplies research-grade tirzepatide (Tirzepatide) and semaglutide (Semaglutide) as laboratory reagents only - not substitutes for the licensed drugs. Both molecules are also on the WADA Prohibited List (S2) and banned in any sanctioned competition.

Buy Semaglutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

Tirzepatide vs Semaglutide: The 2026 Research Comparison

The Three-Sentence Summary

The Side-by-Side Comparison

The Mechanism Difference, Plain

The Head-to-Head Evidence: SURPASS-2

The Obesity Cross-Trial Comparison

Side-Effect Profile: Roughly Similar

The Cost & Access Reality

What This Means for Comparison Research

Related Reading

From the Lab - Peptides on LinkedIn & Facebook

Tirzepatide and Semaglutide, Lab-Verified.

Buy Semaglutide from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide